Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
J. Lu.
Statistical aspects of evaluating treatment and prognostic factors for clinically localized prostate cancer.
Semin Urol Oncol, 18 (2000), pp. 83-92
[2.]
C.D. Vera Donoso, J.F. Jiménez Cruz.
Tumores del riñón, próstata y vías urinarias.
Medicine, 6 (1994), pp. 2851-2858
[3.]
R.S. DiPaola, P. Kumar, W.N. Hait, R.E. Weiss.
State-of-the-art prostate cancer treatment and research. A report from the Cancer Institute of New Jersey.
N J Med, 98 (2001), pp. 23-33
[4.]
E.R. Greenberg.
Incidence and treatment modifications in the prostate carcinoma.
Lancet, 343 (1993), pp. 251-254
[5.]
Anónimo.
INE.
Defunciones según la causa de muerte, (1990),
[6.]
V. Sánchez, J.M. Borrás, M. Mingot.
Evolución de la mortalidad por cáncer en Cataluña: 1975-1990.
Med Clin (Barc), 102 (1994), pp. 606-612
[7.]
S.M. Landis, T. Murria, S. Bolden, et al.
Cancer statistics, 1999.
CA Cancer J Clin, 49 (1999), pp. 8-31
[8.]
J.S. Montgomery, D.K. Price, W.D. Figg.
The androgen receptor gene and its influence on the development and progression of prostate cancer.
J Pathol, 195 (2001), pp. 138-146
[9.]
J.E. Johansson, H.O. Adami, O. Andersson, R. Bergstrom, L. Holmberg, V.B. Krusemo.
High 10-years survival rate in patients with early untreated prostatic cancer.
JAMA, 267 (1992), pp. 2191-2296
[10.]
W.A. Sakr, G.P. Haas, B.F. Cassin, J.E. Pontes, J.D. Crissman.
The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients.
J Urol, 150 (1993), pp. 379-385
[11.]
S.A. Nardo, A. Dupont, L. Cusan, P. Diamond, J.L. Gómez, R. Suburu, et al.
The impact of family history on early detection of prostate cancer.
Nature Medicine, 1 (1995), pp. 99-101
[12.]
M.R. Spitz, R.D. Currier, J.J. Fuefer, F.J. Babden, G.R. Newell.
Familial patterns of prostate cancer: A case control analysis.
J Urol, 146 (1981), pp. 1305-1307
[13.]
J.P. Elo, T. Visakorpi.
Molecular genetics of prostate cancer.
Ann Med, 33 (2001), pp. 130-141
[14.]
E.M. Rosen, S. Fan, I.D. Goldberg.
BRCA1 and prostate cancer.
Cancer Invest, 19 (2001), pp. 396-412
[15.]
N.J. Pienta, P.S. Esper.
Risk factors for prostate cancer.
Ann Intern Med, 118 (1993), pp. 793-803
[16.]
A. Farkas, S. Marcella, G.G. Rhoads.
Ethnic and racial differences in prostate cancer incidence and mortality.
Ethn Dis, 10 (2000), pp. 69-75
[17.]
O.W. Brawley, H. Parnes.
Prostate cancer prevention trials in the USA.
Eur J Cancer, 36 (2000), pp. 1312-1315
[18.]
R.K. Ross, L. Bernstein, R.A. Lobo, H. Shimizu, F.Z. Stanczyk, M.C. Pike, B.E. Henderson.
Actividad de la 5-alfa-reductasa y riesgo de cáncer de próstata en varones japoneses y americanos de raza blanca y negra.
Lancet, 21 (1992), pp. 125-127
[19.]
Editorial. Vasectomía y cáncer de próstata.
Lancet, 19 (1991), pp. 280-281
[20.]
M.P. Waalkes, S. Rem, A.O. Perantoni, T.P. Coogan.
Cadmium exposure in rats and tumours of the eprostate.
IARC Sci Publ, 118 (1992), pp. 391-400
[21.]
X.Y. Zhao, D. Feldman.
The role of vitamin D in prostate cancer.
Steroids, 66 (2001), pp. 293-300
[22.]
J.E. Montie, K. Pienta.
Review of the role of androgenic hormones in the epidemiology of benign prostatic hyperplasia and prostate cancer.
Urology, 43 (1994), pp. 892-899
[23.]
F. Pagano, F. Zattoni, M. Vianello, R. Piazza, G. Capitano.
Is there a relatioship between benign prostatic hyperplasia and prostatic cancer?.
Eur J Urol, 29 (1991), pp. 31-35
[24.]
M. De la Torre, M. Haggman, S. Brandstedt, C. Busch.
Prostatic intraepithelial neoplasia and invasive carcinoma in total prostatectomy specimens: distribution, volumes and DNA ploidy.
Br J Urol, 71 (1993), pp. 984-991
[25.]
W.A. Sakr, A.W. Partin.
Histological markers of risk and the role of high-grade prostatic intraepithelial neoplasia.
Urology, 57 (2001), pp. 115-120
[26.]
J.R. Marshall.
High-grade prostatic intraepithelial neoplasia as an expossure biomarker for prostate cancer chemoprevention research.
IARC Sci Publ, 154 (2001), pp. 191-198
[27.]
J.E. McNeal.
Prostatic microcarcinomas in relation to cancer origin and the evolution to clinical cancer.
Cancer, 71 (1993), pp. 984-991
[28.]
L.C. Cotello, R.B. Franklin.
Bioenergetic theory of prostate malignancy.
Prostate, 25 (1994), pp. 162-166
[29.]
L. Picurelli, P.V. Olcina, M.D. Roig, J. Ferrer, F.e. Determinación de, Mg.
Cu y Zn en tejido prostático normal y patológico.
Actas Urol Esp, 15 (1991), pp. 344-350
[30.]
A.M. De Marzo, M.J. Putzi, W.G. Nelson.
New concepts in the pathology of prostatic epithelial carcinogenesis.
Urology, 57 (2001), pp. 103-114
[31.]
J.L. Amiel, J. Rouëssé, D. Madrover.
Cáncer de próstata.
Manual de Oncología, pp. 200-204
[32.]
G. Bonnadonna.
Carcinoma de próstata.
Manual de Oncología Médica, pp. 585-590
[33.]
M. Puyol Pallas, F. Badía, J. Gómez Parada.
Carcinoma escamoso de próstata.
Actas Urol Esp, 25 (2001), pp. 71-73
[34.]
M.L. Cher.
Mechanisms governing bone metastasis in prostate cancer.
Curr Opin Urol, 11 (2001), pp. 483-488
[35.]
J.E. Johansson, S.O. Andersson, U.B. Krusemo, H.D. Adami, R. Bergström, W. Kraaz.
Historia natural del cáncer de próstata localizado.
Lancet, 15 (1989), pp. 94-98
[36.]
J. Adolfsson, J. Carstensen.
Natural course of clinically localized prostate adenocarcinoma in men less than 70 years old.
J Urol, 146 (1991), pp. 96-98
[37.]
P.C. Smith, A. Hobisch, D.L. Lin, Z. Culig, E.T. Séller.
Interleukin-6 and prostate cancer progression.
Cytokine Growth Factor Rev, 12 (2001), pp. 33-40
[38.]
A.D. Deitch, G.J. Miller, R.W. de Vere White.
Significance of abnormal diploid DNA histograms in localized prostate cancer and asjacent benign prostatic tissue.
Cancer, 72 (1993), pp. 1692-1700
[39.]
J.M. Blancafort Camprodon, J. Contreras García, N. Serrallach Mila.
Adenoma de próstata. Tratamiento médico.
JANO, 47 (1994), pp. 41-46
[40.]
E. Varenhorst, P. Carlsson, E. Capik, O. Lofman, K.V. Pedersen.
Repeated screening for carcinoma of the prostate by digital rectal examination in a randomly selected population.
Acta Oncol, 31 (1992), pp. 815-821
[41.]
E. Varenhorst, K. Berghund, O. Lofman, K. Pedersen.
Interobserver variation in assessment of the prostate by digital rectal examination.
Br J Urol, 72 (1993), pp. 173-176
[42.]
M. Palken, O.E. Cobb, C.E. Simons, B.H. Warren, H.C. Aldape.
Prostate cancer: comparison of digital rectal cancer: comparison of digital rectal examination and transrectal ultrasound for screening.
J Urol, 145 (1991), pp. 86-90
[43.]
J.W. Mold, D.R. Holtgrave, R.S. Bisonni, D.S. Marley, R.A. Wrigth, S.J. Spann.
The evaluation and treatment of men with asymptomatic prostate nodules in primary care: a decision analysis.
J Fam Prac, 34 (1992), pp. 561-568
[44.]
E. Casas Terrón, M. Marí Ruiz, E. Molina Andreu.
Valoración de marcadores tumorales en el diagnóstico del cáncer de próstata.
Arch Esp Urol, 46 (1993), pp. 99-103
[45.]
E.H. Cooper, M.R. Robinson, P. Whelan, M.A. Ferro.
Tumor markers in prostate cancer.
Cancer, 70 (1992), pp. 225-229
[46.]
E.P. Diamandis.
Prostate specific antigen: a cancer ighter and a valuable messenger?.
Clin Chem, 46 (2000), pp. 896-900
[47.]
A. Albarrán, F. Suero, M.J. Baz, A. Cidoncha.
Antígeno prostático específico.
Medicina Integral, 25 (1995), pp. 267-270
[48.]
S. Egawa.
Detection of prostate cancer by prostate specific antigen.
Biomed Pharmacother, 55 (2001), pp. 130-134
[49.]
M. Perrotti.
Understanding PSA and prostate cancer risk assessment.
N J Med, 98 (2001), pp. 35-38
[50.]
P.D. Miller, I. Eardley, R.S. Kirby.
Prostate specific antigen and bone scan correlation in the ataging and monitoring of patients with prostatic cancer.
Br J Urol, 70 (1992), pp. 295-298
[51.]
J.E. Oesterling, S.J. Jacobsen, C.h.G. Chute, H.A. Guess, C.J. Girman, L.A. Panser, et al.
Antígeno específico de próstata sérico en una población de varones sanos en la comunidad.
JAMA, 2 (1993), pp. 755-760
[52.]
J.N. Kabalin.
Antígeno prostático específico; su utilidad clínica.
Modern Geriatrics, 5 (1993), pp. 58-64
[53.]
J.E. Oesterling, S.K. Martín, E.J. Bergtralh, F.C. Lowe.
The use of prostate-specific antigen in standing patients with newly diagnosed prostate cancer.
JAMA, 269 (1993), pp. 57-60
[54.]
J.E. Oesterling, D.C. Rice, W.J. Glenski, E.J. Bergstrlh.
Effect of cystoscopy, prostate biopsy and transuretral resection of prostate on serum prostate-specific antigen concentration.
Urology, 42 (1993), pp. 276-282
[55.]
A.F. Nash, I. Melezinek.
The role of prostate specific antigen measurement in the detection and management of prostate cancer.
Endocr Relat Cancer, 7 (2000), pp. 37-51
[56.]
A.S. Adamson, P. Luckert, M. Polard, M.E. Snell, M. Amirkhosravi, J.L. Francis.
Procoagulant activity may be a marker of the malignant phenotype in experimental prostate cancer.
Br J Cancer, 69 (1994), pp. 286-290
[57.]
S. Takahashi, J. Qian, J.A. Brown, A. Alcaraz, D.G. Bostwick, M.M. Lieber, et al.
Potential markers of prostate cancer aggressiveness detected by fluorescence in situ hybridization in needle biopsies.
Cancer Res, 54 (1994), pp. 3574-3579
[58.]
R.B. Myers, R.F. Meredith, J. Schlom, A.F. Lo Buglio, A.J. Bueschen, R.H. Wheeler, et al.
Tumor associated glycoprotein-72 in highly expressed in prostatic adenocarcinomas.
J Urol, 1152 (1994), pp. 243-246
[59.]
E.A. El Gabry, E.J. Halpern, S.E. Strup, L.G. Gomella.
Imaging prostate cancer: current and future applications.
Oncology, 15 (2001), pp. 325-336
[60.]
J.J. De la Rosette, R.G. Aarrnink.
New developments in ultrasonography for the detection of prostate cancer.
J Endourol, 15 (2001), pp. 93-104
[61.]
J. Kurhanewicz, D.B. Vigneron, S.J. Nelson.
Three-dimensional magnetic resonance spectroscopic imaging and prostate cancer.
Neoplasia, 2 (2000), pp. 166-189
[62.]
M.M. Stilmant, E. Kuligowska.
Transrectal ultrasound screening for prostatic adenocarcinoma with histopathological correlation. Factor affecting specificity.
Cancer, 71 (1993), pp. 2041-2047
[63.]
M.K. Terris, F.S. Freiha, J.E. Mc Neal, T.A. Stamey.
Efficacy of transrectal ultrasound for identification of clinically undetected prostate cancer.
J Urol, 146 (1991), pp. 78-83
[64.]
P. Hammerer, H. Huland.
Systematic sextant biopsies in 651 patients referred for prostate evaluation.
J Urol, 151 (1994), pp. 99-102
[65.]
R. Simak, M. Eisemmenger, A. Hainz, C. Kratzik, M. Marberger.
Is transrectal ultrasonography needed to rule out prostatic cancer with normal findings at digital rectal examination and normal serum prostate specific antigen.
Eur Urol, 24 (1993), pp. 474-478
[66.]
G. Aus, C.G. Hermansson, J. Hugosson, K.V. Pedersen.
Transrectal ultrasound examination of the prostate. Complications and acceptance by patients.
Br J Urol, 71 (1993), pp. 457-459
[67.]
P.J. Littrup, S.E. Bailey.
Prostate cancer: the role of transrectal ultrasound and its impact on cancer.
Radiol Clin North Am, 38 (2000), pp. 87-113
[69.]
S.A. Rosenthal, M.K. Haseman, T.J. Polascik.
Utilkity of capromab pentidine (ProstaScint) imaging in the management of prostate cancer.
Tech Urol, 7 (2001), pp. 27-37
[70.]
P.T. Scardino, R. Weaver, M.A. Hudson.
Early detection of prostate cancer.
Human Pathol, 23 (1992), pp. 211-222
[71.]
Editorial. Cáncer de Próstata.
Tiempos Médicos, 500 (1994), pp. 66
[72.]
J.C. Presti.
Prostate cancer: assessment of risk using digital rectal examination, tumor grade, prostate specific antigen, and systematic biopsy.
Radiol Clin North Am, 38 (2000), pp. 49-58
[73.]
T.M. Pisansky, B.J. Davis.
Predictive factors in localized prostate cancer: implications for radiotherapy and clinical trial design.
Semin Urol Oncol, 18 (2000), pp. 93-107
[74.]
P.J. Subías Lorén, MC. Ginés García.
Aspectos generales del cribado del cáncer.
FMC, 2 (1995), pp. 61-67
[75.]
F. Labrie.
Screening and hormonal therapy of localized prostate cancer shows major benefits on survival.
Cancer J Sci Am, 6 (2000), pp. S182-S187
[76.]
F. Labrie.
Screening and early hormonal treatment of prostate cancer are accumulating srong evidence and support.
Prostate, 43 (2000), pp. 215-222
[77.]
D.E. Neal, H.Y. Leung, P.H. Powell, F.C. Hamdy, J.L. Donovan.
Unanswered questions in screening for prostate cancer.
Eur J Cancer, 36 (2000), pp. 1316-1321
[78.]
F.C. Hamdy.
Prognostic and predictive factors in prostate cancer.
Cancer Treat Rev, 27 (2001), pp. 143-151
[79.]
E.J. Small.
Detección precoz del cáncer de próstata.
Modern Geriatrics, 6 (1994), pp. 153-158
[80.]
K. Okihara, R.J. Babaian.
Early detection of prostate cancer: is PSA a reliable option?.
Tex Med, 97 (2001), pp. 59-62
[81.]
S.R. Gambert.
Prostate cancer. When to offer screening in the eprimary care setting.
Geriatrics, 56 (2001), pp. 22-31
[82.]
J. Martínez de Hurtado, G. Chéchile, H. Villavicencio.
Diagnóstico precoz del cáncer de próstata: estado actual.
Med Clin (Barc), 102 (1994), pp. 708-714
[84.]
R.S. Kirby, M.G. Kirby, M.R. Feneley, T. McNicholas, A. McLean, J.A. Webb.
Screening for carcinoma of the prostate: a GP based study.
Br J Urol, 74 (1994), pp. 64-71
[85.]
D.J. Littrup, A.C. Goodman, C.J. Mettlin.
The benefit and cost of prostate cancer early detection. The Investigators of the American Cancer Society-National Prostate Cancer Detection Project.
CA Cancer Clin, 43 (1994), pp. 134-149
[86.]
H.O. Adami, J.A. Baron, K.J. Rothman.
Aspectos éticos en un ensayo sobre cribado del cáncer de próstata.
Lancet, 25 (1992), pp. 185-187
[87.]
M.D. Krahn, J.E. Mahoney, M.H. Eckeman, J. Tachtenberg, S.G. Pauker, A.S. Detsky.
Pruebas de detección en el cáncer de próstata: análisis de una decisión.
JAMA, 4 (1995), pp. 179-190
[89.]
D.G. Bostwick, D.J. Grignon, M.E. Hammond, M.B. Amin, M. Cohen, D. Crawford, et al.
Prognostic factors in prostate cancer. College of American Pathologists Consensus Statement 1999.
Arch Pathol Lab Med, 124 (2000), pp. 995-1000
[90.]
L.J. Denis, K. Griffiths.
Endocrine treatment in prostate cancer.
Semin Surg Oncol, 18 (2000), pp. 52-74
[91.]
S.B. Malkowicz.
The role of diethylstilbestrol in the treatment of prostate cancer.
Urology, 58 (2001), pp. 108-113
[92.]
J.E. Altwein.
The combination of LH-RH analogues with other treatment modalities in prostate cancer.
Recent Results Cancer Res, 15 (2000), pp. 371-381
[93.]
K.A. Harris, E.J. Small.
Hormonal treatment for prostate cancer.
Expert Opin Investig Drugs, 10 (2001), pp. 493-510
[94.]
G.J. Kolvenbag, P. Iversen, D.W. Newling.
Antiandrogen monotherapy: a new form of treatment for patients with prostate cancer.
Urology, 58 (2001), pp. 16-23
[95.]
D.P. Lubeck, G.D. Grossfeld, P.R. Carroll.
The effect of androgen deprivation therapy on health-related quality of life in men with prostate cancer.
Urology, 58 (2001), pp. 94-100
[96.]
H.W. Daniell.
Osteoporosis due to androgen deprivation therapy in men with prostate cancer.
Urology, 58 (2001), pp. 101-107
[97.]
T. Cook, W.P. Sheridan.
Development of GnRH antagonists for prostate cancer: new approaches to treatment.
Oncologist, 5 (2000), pp. 162-168
[98.]
J. Barton, G. Blackledge, A. Wakeling.
Growth factors and their receptors: new targets for prostate cancer therapy.
Urology, 58 (2001), pp. 114-122
[99.]
R. Lieberman.
Androgen deprivation therapy for prostate cancer chemoprevention: current status and future directions for agent development.
Urology, 58 (2001), pp. 83-90
[100.]
M. Laufer, S.R. Denmeade, V.J. Sinibaldi, M.A. Carducci, M.A. Eisenberger.
Complete androgen blockade for prostate cancer: what went wrong?.
J Urol, 164 (2000), pp. 3-9
[101.]
P.S. Marschke.
The role of surgery in the treatment of prostate cancer.
Semin Oncol Nurs, 17 (2001), pp. 85-89
[102.]
R.R. Iwamoto, K.E. Mahler.
Radiation therapy for prostate cancer.
Semin Oncol Nurs, 17 (2001), pp. 90-100
[103.]
T.A. Dipetrillo.
Three-dimensional conformal radiotherapy for early stage prostatic cancer: techniques, outcomes, and possible pitfalls.
Surg Oncol Clin N Am, 9 (2000), pp. 435-453
[104.]
M.J. Szostak, N. Kyprianou.
Radiation-induced apoptosis: predictive and therapeutic significance in radiotherapy of prostate cancer (review).
Oncol Rep, 7 (2000), pp. 699-706
[105.]
G.S. Cherr, C. Hall, B.C. Pineau, G.S. Waters.
Rectourethral fistula and massive rectal bleeding from iodine-125 prostate brachytherapy: a case report.
Am Surg, 67 (2001), pp. 131-134
[106.]
I.G. Vainas.
Octeotride in the management of hormone-refractory prostate cancer.
Chemotherapy, 47 (2001), pp. 109-126
[107.]
D.P. Petrylak.
Docetaxel (Taxotere) in hormone-refractory prostate cancer.
Semin Oncol, 27 (2000), pp. 24-29
[108.]
E.J. Small.
Docetaxel in prostate cancer.
Aticancer Drugs, (2001), pp. S17-S20
[109.]
A. Heidenreich, R. von Knobloch, R. Hofmann.
Current Stataus of cytotoxic chemotherapy refractory prostate cancer.
Eur Urol, 39 (2001), pp. 121-130
[110.]
J.F. Pirani.
The effects of phytotherapeutic agents on prostate cancer: an overview of recent clinical trials of PC SPES.
Urology, 58 (2001), pp. 36-38
[111.]
M.S. Steiner, J.R. Gingrich.
Gene therapy for prostate cancer: where are we now?.
J Urol, 164 (2000), pp. 1121-1136
Copyright © 2002. Elsevier España, S.L. y Sociedad Española de Medicina Rural y Generalista (SEMERGEN)
